·tradingview.comMed
aTyr Pharma Files Supplement for Up to $79.99 Million Stock Offering
aTyr Pharma filed a supplement to sell up to $79.99 million of common stock under its Open Market Sale Agreement with Jefferies LLC, per an SEC filing.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ATYR
aTYR PHARMA INC
aTYR Pharma is a clinical-stage biotechnology company developing therapies for fibrosis and inflammation using its discovery platform based on tRNA synthetase biology. Its lead candidate, efzofitimod, is an immunomodulator in clinical development for interstitial lung disease, including pulmonary sarcoidosis and systemic sclerosis-associated ILD. The company is also studying efzofitimod in a Phase 2 trial for systemic sclerosis-associated ILD. Its preclinical pipeline includes ATYR0101, a fusion protein candidate for fibrotic diseases, and ATYR0750, a fusion protein that interacts with FGFR4. aTYR Pharma researches candidates through internal discovery and external collaborations. Under an agreement with Kyorin Pharmaceutical, Kyorin holds exclusive rights to develop and commercialize efzofitimod for all forms of ILD in Japan and funds activities there; aTYR Pharma supplies the drug product and supports development. The agreement provides for milestone payments and tiered royalties on Japanese net sales. aTYR Pharma is headquartered in San Diego, California.
Price · $ATYRvia TradingView
AI sentiment · 7d6 articles
- Bullish
- 1
- Neutral
- 2
- Bearish
- 3
Insider · 30dAll trades →
No SEC Form 4 filings for $ATYR in the last 30 days.
See all $ATYR insider activity →Top stories · $ATYRMore →
·SEC EDGAR 8-K
ATyr Pharma, Inc. filed a prospectus supplement related to the sale of the Company’s common stock, par value $0.001 per share with the Securities and…
aTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 6, 2026, aTyr Pharma, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) related to the sale of the Company’s common stock, par value $0.001 per share (the “Common Stock”) with the Securities and Exchange Commissio
·tradingview.com
RBC Capital maintains aTyr Pharma at Sector Perform, lowers price target to $6 from $40
RBC Capital downgraded aTyr Pharma to Sector Perform, reducing its price target from $40 to $6, an 85% decrease. This aligns with the stock's recent close at $6.03, according to the firm.
ATYR sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning ATYR (aTYR PHARMA INC). Coverage has skewed bearish: 1 bullish, 2 neutral, and 3 bearish.
Recent ATYR coverage spans financial news, corporate actions and earnings.
What's driving ATYR
The new equity offering could dilute existing shareholders and increase cash for the company.
The authorized secondary offering increases share supply and may dilute existing shareholders.
Analyst downgrade suggests significant downside risk.
Analyst upgrade may boost investor interest and support price gains.
Target cut suggests lower valuation expectations, likely pressuring the stock lower.
AlphAI scores every news story that mentions ATYR with an AI model for sentiment and relevance, and aggregates insider trades from aTYR PHARMA INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ATYR
Score
aTyr Pharma Files Supplement for Up to $79.99 Million Stock Offering
aTyr Pharma filed a supplement to sell up to $79.99 million of common stock under its Open Market Sale Agreement with Jefferies LLC, per an SEC filing.
ATyr Pharma, Inc. filed a prospectus supplement related to the sale of the Company’s common stock, par value $0.001 per share with the Securities and…
aTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 6, 2026, aTyr Pharma, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) related to the sale of the Company’s common stock, par value $0.001 per share (the “Common Stock”) with the Securities and Exchange Commissio
RBC Capital maintains aTyr Pharma at Sector Perform, lowers price target to $6 from $40
RBC Capital downgraded aTyr Pharma to Sector Perform, reducing its price target from $40 to $6, an 85% decrease. This aligns with the stock's recent close at $6.03, according to the firm.
Wells Fargo maintains aTyr Pharma at Equal-Weight, raises price target to $4 from $1
Wells Fargo kept aTyr Pharma at Equal-Weight, raising its price target to $4 from $1, a 300% increase. This implies a 33.7% downside from the Nov 5 close of $6.03, according to the bank.
Piper Sandler lowers aTyr Pharma stock price target on valuation
Piper Sandler cut aTyr Pharma's (ATYR) price target to $35 from $280, keeping an Overweight rating. The biotech firm's stock trades at $6.03, down over 80% in a year. The firm adjusted its target after aTyr's Q3 2026 earnings report, which included Phase 3 trial updates for efzofitimod. aTyr ended Q3 2026 with $50.3M in cash. The company announced a 1-for-40 reverse stock split, effective October 28.
aTYR PHARMA INC (ATYR): Results of Operations and Financial Condition
aTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Ashlee Dunston Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update Reached alignment with FDA on proposed Phase 3 study of efzofitimod in pulmonary sarcoidosis with rest
aTyr publishes phase 3 pulmonary sarcoidosis trial results
aTyr Pharma (NASDAQ:ATYR) published Phase 3 trial results for efzofitimod in pulmonary sarcoidosis in The Lancet Respiratory Medicine. The study did not meet its primary endpoint of steroid reduction but showed clinical benefits in patient-reported outcomes. The drug was well-tolerated and maintained lung function. The company is also investigating efzofitimod in other conditions.
aTyr Pharma to implement 1-for-40 reverse stock split
aTyr Pharma (NASDAQ:ATYR) will implement a 1-for-40 reverse stock split, effective Wednesday, to meet Nasdaq's minimum bid price requirement. Shares will trade under the same symbol with a new CUSIP. Outstanding shares will reduce from 100.5 million to 2.5 million. The company's board approved the split, which was ratified by stockholders in October 2026. The action does not change ownership percentages, except where fractional shares result.
aTyr Pharma, Inc. Stock 12‑Month Price Target Raised to $3.2, Implies 1757% Upside
Analysts raised aTyr Pharma's 12-month price target to $3.2, up from $2.83, with estimates ranging from $1 to $7. This implies a 1757% upside from the Oct. 21 closing price. The consensus rating remains 'Buy' among 7 analysts, with 3 Buys and 4 Holds.
aTyr Pharma partners with Einstein on cancer research
aTyr Pharma (NASDAQ:ATYR) partners with Albert Einstein College of Medicine to research ATYR2810, a monoclonal antibody targeting NRP2 in pediatric osteosarcoma. The collaboration aims to evaluate NRP2's role in bone cancers, with ATYR2810 showing anti-tumor effects in preclinical models. aTyr Pharma is a biotech company focused on tRNA synthetase-based therapies.